A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas

An Open-label Study of Fludarabine and Cyclophosphamide Plus MabThera Followed by Maintenance With MabThera on Failure-free Survival in Treatment-naïve Patients With Advanced Indolent B-cell Nonfollicular Lymphoma

This study will evaluate the efficacy and safety of MabThera in combination chemotherapy, followed by maintenance treatment with MabThera. The anticipated time on study treatment is 1-2 years, and the target sample size is <100 individuals.

Inclusion Criteria:

• adult patients 18-65 years of age;
• previously untreated indolent nonfollicular non-Hodgkin's lymphoma;
• active disease;
• >=3 involved sites.

Exclusion Criteria:

• typical chronic lymphocytic leukemia;
• other malignancies within 3 years before study, except basal or squamous cell skin cancer or cancer in situ of the cervix;
• systemic corticosteroid use for >1 month;
• significant cardiovascular disease;
• central nervous system involvement;
• hepatitis B or C virus infection, or HIV infection.